Study Summary
This trial assesses safety & effectiveness of an experimental drug combo to treat advanced lung cancer in adults. Safety lead-in of 10-20 patients, then 50-60 total.
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer (NSCLC), Recurrent
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 4 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Experimental Group
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Experimental Group · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 14 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this investigation accepting new participants?
"According to the current information on clinicaltrials.gov, this medical experiment is actively seeking participants with postings first made on February 17th 2023 and most recently updated February 23rd." - Anonymous Online Contributor
Has the FDA approved Experimental Group's products for use?
"Our team at Power approximated the safety of Experimental Group with a score of 2, as this is only in Phase 2. Thus far, there has been data to support its safety but not its efficacy." - Anonymous Online Contributor
Is there a finite limit to the number of volunteers taking part in this clinical experiment?
"Affirmative. The clinical trial, posted on February 17th 2023 and most recently revised on the 23rd of the same month, is actively seeking participants according to data hosted by clinicaltrials.gov. In total, 50 individuals are being recruited from 1 medical centre." - Anonymous Online Contributor
What outcomes is this research attempting to accomplish?
"This 3-year clinical trial is designed to measure the incidence and magnitude of adverse events. Pharmacokinetic analysis will be used to assess three secondary outcomes: 1) The time it takes for GT103 to reach its peak concentration when administered with Pembrolizumab (Tmax); 2) The maximum serum concentration of GT103 after administration in combination with Pembrolizumab (Cmax); and, 3) Area under the plasma concentration vs time curve (AUC)." - Anonymous Online Contributor